Synthetica Bio Launches with Venture Funding to Develop a Generative AI Platform Purpose-Built for Biopharma
LAGUNA BEACH, Calif., June 27, 2023 /PRNewswire/ -- Synthetica Bio, a privately held healthcare technology company developing an enterprise-grade, generative artificial intelligence (GenAI) platform for biopharma, today announced the official launch of the company and new capital as part of its seed funding. The company is led by Simon Arkell, OLY/MBA and Alex Dickinson, Ph.D., healthcare technology pioneers who have built successful companies including Predixion, Deep Lens, Luxtera, Helixis, and Chromacode. Synthetica Bio is focused on meeting the accelerating demand to provide actionable knowledge to biopharma companies to drive drug development, clinical trials, and commercial activity in a safe and efficient manner.
- Synthetica Bio's venture funding was led by Virtue, with participation from AIX Ventures, Page One Ventures, and additional strategic investors.
- Proceeds from the financing will support development and expansion of the Synthetica Bio platform.
- In the new era of GenAI, Synthetica Bio is enabling biopharma companies to use AI responsibly, initially serving commercial teams within this sector.
- Our aim is to make the Synthetica Bio platform the central destination for biopharma companies to rapidly and cost-effectively gain actionable insights into data from any source," added Dr. Dickinson, Executive Chair of Synthetica Bio.